1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Huge market demand
4.1.2 Higher profitability and improved technology
4.1.3 Government funded projects and Associations
4.1.4 Increasing demand, higher onset of diseases
4.2 Restraints
4.2.1 High regulatory intervention and cost
4.2.2 Increasing demand for cost-effective vaccines
4.3 Opportunities
4.3.1 New Target Populations-shift from established markets to lesser developed markets
4.4 Challenges
4.4.1 Difficult in development process
5. Europe Preventive Vaccines Market- By Type of Vaccine
5.1 Recombinant Vector Vaccines
5.2 DNA Vaccines
5.3 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 Subunit Vaccines
5.6 Inactivated Vaccines
5.7 Live, Attenuated Vaccines
6. Europe Preventive Vaccines Market-By Applications
6.1 Pediatric Vaccine
6.1.1 Combinations Vaccines
6.1.1.1 Bivalent Vaccines
6.1.1.2 Trivalent Vaccines
6.1.1.3 Tetravalent Vaccines
6.1.1.4 Pentavalent Vaccines
6.1.2 HIB
6.1.3 Hepatitis
6.1.4 Poliovirus
6.1.5 MMR
6.1.6 Varicella Vaccines
6.1.7 Pneumococcal Vaccines
6.1.8 Others
6.2 Adult Vaccine
6.2.1 Zoster
6.2.2 Hepatitis
6.2.3 Cervical Cancer
6.2.4 Influenza
6.2.5 Others
7. Europe Preventive Vaccines Market - By Country
7.1.Introduction
7.2.UK
7.3.Germany
7.4. France
7.5 Rest of Europe
8. Company Profiles
8.1 Novartis AG
8.2 Johnson and Johnson
8.3 MedImmune, LLC
8.4 Pfizer, Inc.
8.5 Sanofi Pasteur
8.6 Emergent BioSolutions Inc.
8.7 CSL Limited
8.8 Bavarian Nordic
8.9 Merck and Company
8.10 GlaxoSmithKline, plc.
9. Europe Preventive Vaccines Market - Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
